Snapshot: March Highlights
Executive Summary
A selection of articles you may have missed from March 2023, including discussion of the benefits and risks of both CAR-T and NK cell therapies, insights into how companies can source financing when VC cash is scarce, and a highlight on Pfizer's mammoth purchase of Seagen.
You may also be interested in...
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.
Deals Shaping The Industry, February 2024
An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.
Execs On The Move: February 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.